Management of Patients With Ocular Hypertension: A Cost-Effectiveness Approach From the Ocular Hypertension Treatment Study

American Journal of Ophthalmology

Volumn 143, Issue 1, 2007, Pages 191-192

  Rosenbaum, Louis J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TIMOLOL;

COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LETTER; MEDICARE; OPHTHALMOSCOPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; REPRODUCIBILITY; TRABECULOPLASTY; TREATMENT INDICATION; VISUAL FIELD;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; UNITED STATES;

EID: 33845488353     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.10.001     Document Type: Letter

References (3)

1. Kymes S.M., Kass M.A., Anderson D.R., Miller J.P., and Gordon M.O. Management of patients with ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study (OHTS). Am J Ophthalmol 141 (2006) 997-1008
2. Kass M.A., Heuer D.K., Higgenbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
3. Peters T.J., and Waterman Jr. R.H. In Search of Excellence: Lessons from America's Best-Run Companies (1982), Harper & Row, New York, New York 400